Zoetis Inc.
ZTSNYSE
$81.76
Last price · USD
- Market cap
- $36.29B
- P/E
- 13.6x
- EV / EBITDA
- 10.7x
- P/S
- 3.8x
- FCF yield
- 6.3%
- Div. yield
- 2.45%
Multiples use last price and FY2025 annual figures. Market cap estimated from diluted shares.
Revenue
$9.47B
+2.3%
4Y CAGR +5.0%
Gross profit
$6.67B
+4.3%
4Y CAGR +5.9%
Operating income
$3.60B
+6.0%
4Y CAGR +6.4%
Net income
$2.67B
+7.5%
4Y CAGR +7.0%
EPS (diluted)
$6.02
+10.1%
4Y CAGR +9.0%
Free cash flow
$2.28B
-0.7%
4Y CAGR +7.1%
Revenue & net income
Fiscal 2021–2025 · USD
RevenueNet income
Valuation
At $81.76 · FY2025 fundamentals
- Market cap
- $36.29B
- Enterprise value
- $43.47B
- P/E
- 13.6x
- P/S
- 3.8x
- P/B
- 10.9x
- EV / EBITDA
- 10.7x
- EV / Sales
- 4.6x
- Earnings yield
- 7.4%
- FCF yield
- 6.3%
- Shareholder yield
- 11.4%
Profitability
Margins as a share of revenue
| Metric | Latest | 4Y ago | Trend |
|---|---|---|---|
| Gross margin | 70.5%+2.2pp | 68.3% | |
| Operating margin | 38.0%+1.9pp | 36.0% | |
| EBITDA margin | 43.0%+2.2pp | 40.8% | |
| Net margin | 28.2%+2.0pp | 26.2% | |
| FCF margin | 24.1%+1.8pp | 22.3% |
Returns & financial health
FY2025 with 4-year trend
| Metric | Latest | 4Y ago | Trend |
|---|---|---|---|
| Return on equity | 80.2% | 44.8% | |
| Return on invested capital | 27.2% | 29.4% | |
| Return on assets | 17.3% | 14.7% | |
| Debt / equity | 2.85x | 1.48x | |
| Net debt / EBITDA | 1.76x | 1.03x | |
| Current ratio | 3.03x | 3.86x |
Cash & equivalents
$2.31B
Total debt
$9.49B
Capital allocation
How ZTS used its cash in FY2025
- Operating cash flow
- $2.90B
- Capital expenditure
- $621M
- Dividends paid
- $889M
- Share repurchases
- $3.23B
- Stock-based compensation
- $83.0M
- Diluted shares
- 443.8M
- Share count change (4Y)
- -6.9%
Analyst estimates
Consensus for upcoming fiscal years
| Fiscal year | Revenue | Growth | EPS | Growth |
|---|---|---|---|---|
| FY2025 actual | $9.47B | $6.02 | ||
| FY2026E9 analysts | $9.27B | -2.1% | $6.21 | +3.2% |
| FY2027E10 analysts | $9.38B | +1.2% | $6.38 | +2.7% |
| FY2028E6 analysts | $9.73B | +3.7% | $6.86 | +7.4% |
About Zoetis Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses.
zoetis.com- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Kristin C. Peck
- Employees
- 14,500
- Headquarters
- Parsippany, NJ, US
- IPO date
- 2013-02-01
Zoetis Inc. (ZTS) — frequently asked questions
Answered from the company's SEC filings
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools.
Explore the full income statement, balance sheet and cash flow statement. Not investment advice.